In a phase II trial of a P53 DC vaccine involving 26 subjects with verified progressive breast cancer, among 19 patients continue treatment after 6 vaccinations weeks, 42% attained SD, indicating an efficacy of p53-specific immune therapy. The gene discussed is TP53; the disease is breast carcinoma.